Global Latisse (Bimatoprost) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Latisse (Bimatoprost) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Latisse (Bimatoprost) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Latisse (Bimatoprost) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Patented Product and General Products are the major drivers for the industry.
Global Latisse (Bimatoprost) (CAS 155206-00-1) key players include Chirogate International, Cayman Pharma, Zhejiang Ausun, Everlight Chemical, and Lianmin Biochemical etc. Global top three players hold a share about 40%. North America is the largest market, with a share about 90%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Latisse (Bimatoprost) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Purity, Application and Regions Listed in the Report
Cayman Pharma
Tecoland Corporation
TCS Group
Changzhou BOHIV
Zhejiang Ausun
Ansion Pharma
Lianmin Biochemical
Chirogate International
Everlight Chemical
GENTEC
Segment by Purity
Below 99.5%
Other
Patented Product
General Products
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Latisse (Bimatoprost) market further
Chapter 1Product Definition, Product Puritys, Volume and Revenue analysis of Each Purity in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Latisse (Bimatoprost), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Latisse (Bimatoprost) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Latisse (Bimatoprost) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Latisse (Bimatoprost) introduction, etc. Latisse (Bimatoprost) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Latisse (Bimatoprost) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Latisse (Bimatoprost) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Latisse (Bimatoprost) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Patented Product and General Products are the major drivers for the industry.
Global Latisse (Bimatoprost) (CAS 155206-00-1) key players include Chirogate International, Cayman Pharma, Zhejiang Ausun, Everlight Chemical, and Lianmin Biochemical etc. Global top three players hold a share about 40%. North America is the largest market, with a share about 90%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Latisse (Bimatoprost) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Purity, Application and Regions Listed in the Report
By Company
Cayman Pharma
Tecoland Corporation
TCS Group
Changzhou BOHIV
Zhejiang Ausun
Ansion Pharma
Lianmin Biochemical
Chirogate International
Everlight Chemical
GENTEC
Segment by Purity
Below 99.5%
Other
Segment by Application
Patented Product
General Products
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Latisse (Bimatoprost) market further
Chapter 1Product Definition, Product Puritys, Volume and Revenue analysis of Each Purity in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Latisse (Bimatoprost), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Latisse (Bimatoprost) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Latisse (Bimatoprost) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Latisse (Bimatoprost) introduction, etc. Latisse (Bimatoprost) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Latisse (Bimatoprost) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices